Amarin Corporation plc Sponsored ADR (AMRN)
Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now
Amarin (AMRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
Here is how Amarin (AMRN) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy
Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/Y
AMRN beats earnings and sales estimates as Vascepa sales rise and cost cuts take hold, while the partnered Europe strategy reshapes growth.
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?
Here is how Amarin (AMRN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know
Amarin shares surge 37.7% in a year as restructuring, cost cuts and expanding Vazkepa partnerships for international growth fuel optimism.
Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss
AMRN swings to Q4 profit and beats estimates, but revenues decline 21% as Vascepa sales slide and shares fall 9% on the mixed results.
Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations
AMRN jumps 17% after Q4 and FY2025 preliminary sales beat expectations. The release also reflected positive Q4 cash flow and progress on cost cuts.
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down
AMRN's third-quarter earnings fall short of expectations, but stronger U.S. Vascepa sales push revenues above estimates.
Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript
Amarin Corporation plc ( AMRN ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Aaron Berg - CEO, President & Director Peter Fishman - Senior VP & CFO Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Mazahir Alimohamed - Leerink Partners LLC, Research Division Presentation Operator Welcome to Amarin Corporation's conference call to discuss its third quarter 2025 financial results. I would like to turn the conference call over to Bob Burrows, Investor Relations for Amarin.
